# Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

> **NCT06022757** · PHASE1,PHASE2 · RECRUITING · sponsor: **Evopoint Biosciences Inc.** · enrollment: 204 (estimated)

## Conditions studied

- Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma
- Prostate Cancer
- Small-cell Lung Cancer
- Non-small Cell Lung Cancer
- Cervical Cancer
- Other Solid Tumors

## Interventions

- **DRUG:** XNW5004
- **DRUG:** KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection

## Key facts

- **NCT ID:** NCT06022757
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-20
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022757, "Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06022757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*